Evaluation of soft-tissue lesions with F-18-FDG PET/CT: initial results of a prospective trial

dc.creatorLeal, AL
dc.creatorEtchebehere, M
dc.creatorSantos, AO
dc.creatorKalaf, G
dc.creatorPacheco, EB
dc.creatorAmstalden, EM
dc.creatorEtchebehere, EC
dc.date2014
dc.dateMAR
dc.date2014-07-30T17:28:11Z
dc.date2015-11-26T16:46:00Z
dc.date2014-07-30T17:28:11Z
dc.date2015-11-26T16:46:00Z
dc.date.accessioned2018-03-28T23:31:44Z
dc.date.available2018-03-28T23:31:44Z
dc.identifierNuclear Medicine Communications. Lippincott Williams & Wilkins, v. 35, n. 3, n. 252, n. 259, 2014.
dc.identifier0143-3636
dc.identifier1473-5628
dc.identifierWOS:000331291000005
dc.identifier10.1097/MNM.0000000000000041
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/65915
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/65915
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1274399
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionPurpose of the reportAlthough MRI is utilized for planning the resection of soft-tissue tumors, it is not always capable of differentiating benign from malignant lesions. The risk of local recurrence of soft-tissue sarcomas is increased when biopsies are performed before resection and by inadequate resections. PET associated with computed tomography using fluorodeoxyglucose labeled with fluorine-18 (F-18-FDG PET/CT) may help differentiate between benign and malignant tumors, thus avoiding inadequate resections and making prior biopsies unnecessary. The purpose of this study was to evaluate the usefulness of F-18-FDG PET/CT in differentiating benign from malignant solid soft-tissue lesions.Materials and methodsPatients with solid lesions of the limbs or abdominal wall detected by MRI were submitted to F-18-FDG PET/CT. The maximum standardized uptake value (SUVmax) cutoff was determined to differentiate malignant from benign tumors. Regardless of the F-18-FDG PET/CT results all patients underwent biopsy and surgery.ResultsMRI was performed in 54 patients, and 10 patients were excluded because of purely lipomatose or cystic lesions. F-18-FDG PET/CT was performed in the remaining 44 patients. Histopathology revealed 26 (59%) benign and 18 (41%) malignant soft-tissue lesions. A significant difference in SUVmax was observed between benign and malignant soft-tissue lesions. The SUVmax cutoff of 3.0 differentiated malignant from benign lesions with 100% sensitivity, 83.3% specificity, 89.6% accuracy, 78.3% positive predictive value, and 100% negative predictive value.Conclusion(18)F-FDG PET/CT seems to be able to differentiate benign from malignant soft-tissue lesions with good accuracy and very high negative predictive value. Incorporating F-18-FDG PET/CT into the diagnostic algorithm of these patients may prevent inadequate resections and unnecessary biopsies. (C) 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
dc.description35
dc.description3
dc.description252
dc.description259
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFAPESP [11/50255-0]
dc.languageen
dc.publisherLippincott Williams & Wilkins
dc.publisherPhiladelphia
dc.publisherEUA
dc.relationNuclear Medicine Communications
dc.relationNucl. Med. Commun.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectF-18-FDG
dc.subjectPET/CT
dc.subjectsarcoma
dc.subjectsoft-tissue tumors
dc.subjectImaging Bone Metastases
dc.subjectEwing Sarcoma
dc.subjectFdg-pet/ct
dc.subjectCancer
dc.subjectBenign
dc.subjectTumors
dc.subjectExtremity
dc.subjectTherapy
dc.subjectMyeloma
dc.subjectSpect
dc.titleEvaluation of soft-tissue lesions with F-18-FDG PET/CT: initial results of a prospective trial
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución